Fictious Healthcare professional

Recommended dosing

ZEJULA (niraparib) is a first-line maintenance treatment that offers your patients convenient once-daily oral dosing1

Could your patients benefit from a once-daily PARP inhibitor with an individualised starting dose?1

Once daily icon

Once-daily oral regimen

Time icon

Take at approximately the same time each day.

Image of two white tablets

A starting dose personalised to patients based on weight and platelet counts

Downward trending arrow

Low potential for drug-drug interactions

Image of two white tablets

One hour before or two hours after food, or with a light meal

ZEJULA (niraparib) is indicated1

  • as monotherapy for the maintenance treatment of adult patients with advanced epithelial (FIGO Stages III and IV) high-grade ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.
  • as monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.

Abbreviations

DDIs, Drug to Drug Interactions; PARP, poly(ADP-ribose) polymerase

Reference

  1. Zejula (niraparib) Summary of product characteristics (Last Accessed: May 2024).

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk (UK) or search for MHRA Yellow Card in the Google Play or Apple App store. Adverse events should also be reported to GSK Limited on 0800 221 441 or by email at uksafety@gsk.com.

©2024 GSK Group of Companies or its licensor. Trademarks are the property of their respective owners.

May 2024 | PM-GB-NRP-WCNT-220024 (V2.0)